---
title: Effects Of Different Anesthesia Applications On Mood, Depression, And Anxiety Levels In Burn Patients
nct_id: NCT06165848
overall_status: COMPLETED
sponsor: T.C. Sağlık Bakanlığı Ankara Bilkent Şehir Hastanesi
study_type: OBSERVATIONAL
primary_condition: Burn Unspecified Degree
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06165848.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06165848"
ct_last_update_post_date: 2023-12-12
last_seen_at: "2026-05-12T06:44:33.019Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effects Of Different Anesthesia Applications On Mood, Depression, And Anxiety Levels In Burn Patients

**NCT ID:** [NCT06165848](https://clinicaltrials.gov/study/NCT06165848)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 67
- **Lead Sponsor:** T.C. Sağlık Bakanlığı Ankara Bilkent Şehir Hastanesi
- **Conditions:** Burn Unspecified Degree, Deep Sedation
- **Start Date:** 2020-07-09
- **Completion Date:** 2021-06-07
- **CT.gov Last Update:** 2023-12-12

## Brief Summary

Adequate and effective pain management and prevention of depression are essential in burn patients. This study aims to investigate the effects of ketamine sedation in burn patients in terms of mood disorders, depression, anxiety, and suicidal tendency during intensive care follow-up in the postoperative period.

## Detailed Description

Aim: Adequate and effective pain management and prevention of depression are essential in burn patients. This study aims to investigate the effects of ketamine sedation in burn patients in terms of mood disorders, depression, anxiety, and suicidal tendency during intensive care follow-up in the postoperative period.

Methods: The study was conducted with 67 patients between 18 and 65 years of age, who were ASA I-II class, had basic communication skills, no previous diagnosis of psychiatric illness, and no history of neuropsychiatric or cognitive disease or related treatment. After preoxygenation, anesthesia induction was performed with 2 mg/kg IV propofol and 1 mcg/kg IV fentanyl in the general anesthesia group. Anesthesia was continued with a mixture of 0.3-0.5 mcg/kg/min remifentanil, 2% sevoflurane, 50% air, 50% oxygen. In the sedation group, 1 mcg/kg IV fentanyl and 1 mg/kg IV ketamine were administered at induction; anesthesia was maintained by adding 30-50 mg IV propofol if necessary. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by the psychiatrist.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Who were ASA I-II class,
* Had basic communication skills,
* No previous diagnosis of psychiatric illness,
* No history of neuropsychiatric or cognitive disease or related treatment.

Exclusion Criteria:

* With a previous diagnosis of psychiatric illness,
* Neuropsychiatric or cognitive illness,
* Or a history of related treatment.
```

## Arms

- **General anesthesia** — After preoxygenation, anesthesia induction was performed with 2 mg/kg IV propofol and 1 mcg/kg IV fentanyl in the general anesthesia group. Anesthesia was maintained with a mixture of 0.3-0.5 mcg/kg/min remifentanil, 2% sevoflurane, 50% air, 50% oxygen. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by a psychiatrist.
- **Sedation anesthesia** — In the sedation group, 1 mcg/kg IV fentanyl and 1 mg/kg IV ketamine were administered at induction, and 30-50 mg IV propofol was added if necessary to maintain anesthesia. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by a psychiatrist.

## Primary Outcomes

- **Montgomery-Asberg Depression Rating Scale (MADRS),** _(time frame: 72 hours)_ — In order to determine whether there is negative mood and depression; Montgomery-Asberg Depression Rating Scale (MADRS) was administered by the psychiatrist .
- **Hamilton Anxiety Rating Scale (HAM-A)** _(time frame: 72 hours)_ — For anxiety; Hamilton Anxiety Rating Scale (HAM-A) was administered by the psychiatrist .
- **Beck Suicidal Ideation Scale (BSSI)** _(time frame: 72 hours)_ — To determine whether there is suicidal ideation; Beck Suicidal Ideation Scale (BSSI) was administered by the psychiatrist .

## Locations (1)

- Ankara Bilkent Şehir Hastanesi, Ankara, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ankara bilkent şehir hastanesi|ankara||turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06165848.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06165848*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*